$RNXT

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.

RenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

Tenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.

Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.

RenovoRx (RNXT) reported peer-reviewed data showing ~51% local drug extraction at the tumor site in a sub-study of its Phase III TIGeR-PaC trial. The study compared intra-arterial gemcitabine (IAG) with intravenous gemcitabine (IVG) in 16 patients with locally advanced pancreatic cancer. IAG resulted in lower systemic exposure and a significant correlation between dFdU levels and CA 19-9 tumor marker reduction. The company reported $1.1M in 2025 sales and $909,000 in Q2 2026 revenue. The stock d

RenovoRx (RNXT) regained Nasdaq compliance after its stock maintained a $1 minimum bid for 10 days. The company reported Q2 revenue of $909,000, expanded its cancer center customer base, and completed enrollment in its Phase 3 TIGeR-PaC trial. RNXT stock closed at $1.32, down 3.77% in pre-market trading.

RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.

RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.